Harish Shantharam is CFO at CymaBay Therapeutics, Inc. (CBAY). They have made 1 open-market trade across 1 company since 2025, most recently 2025-08-18.
CIK 0001976391
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $59K since 2025, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALXO | BUY | 2025-08-18 | 2025-08-20 | $0.78 | $59K | +19.7% | +40.7% | +89.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.